Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Red cell antibodies arising from solid organ transplants.

G Ramsey1

  • 1Central Blood Bank, Pittsburgh, Pennsylvania.

Transfusion
|January 1, 1991
PubMed
Summary

Red blood cell (RBC) antibodies can complicate solid organ transplants, especially ABO-unmatched cases. While often self-limiting, these graft antibodies can cause hemolysis, and in rare instances, acute renal failure.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood component transfusions in mass casualty events.

Vox sanguinis·2017
Same author

Morphometry and abnormalities of the feet of Kaimanawa feral horses in New Zealand.

Australian veterinary journal·2010
Same author

Promoting Global Research Excellence in Severe Sepsis (PROGRESS): lessons from an international sepsis registry.

Infection·2009
Same author

Legal, financial, and public health consequences of transfusion-transmitted hepatitis C virus in persons with haemophilia.

Vox sanguinis·2007
Same author

CD34(+) cell collection efficiency does not correlate with the pre-leukapheresis hematocrit.

Bone marrow transplantation·2001
Same author

A normal aPTT does not guarantee adequate coagulation factor levels.

Anesthesiology·2001

Area of Science:

  • Immunohematology
  • Transplantation Immunology
  • Solid Organ Transplantation

Background:

  • Red blood cell (RBC) antibodies directed against recipient RBCs are a known complication of solid organ transplantation.
  • The incidence and severity of these antibodies and subsequent hemolysis correlate with organ size (lymphoid content) in ABO-unmatched transplants.
  • Specific patient populations and immunosuppressive regimens influence the frequency of hemolysis.

Purpose of the Study:

  • To review the occurrence and characteristics of RBC antibodies arising from transplanted organs.
  • To analyze factors influencing the development and severity of hemolysis post-transplant.
  • To discuss management strategies and clinical outcomes associated with these immunohematologic complications.

Main Methods:

  • Review of clinical cases involving RBC antibodies and hemolysis after solid organ transplantation.
  • Analysis of patient data, including transplant type, ABO compatibility, immunosuppressive therapy, and clinical outcomes.
  • Examination of antibody characteristics (type, onset, duration) and transfusion strategies.

Main Results:

  • Hemolysis frequency increased in cyclosporine-treated kidney recipients and O-to-A liver recipients, but decreased in group AB liver recipients and those on azathioprine or low-dose irradiation.
  • ABO antibodies (typically IgG) appear 7-10 days post-transplant and last about a month; Rh antibodies can last 2-6 months.
  • While most cases require only transfusions, severe hemolysis can lead to acute renal failure or death; graft survival may be reduced in some cases.

Conclusions:

  • RBC antibodies post-transplant are a significant immunohematologic concern, particularly in ABO-unmatched scenarios.
  • Immunosuppressive therapy and organ type play a role in the incidence and severity of hemolysis.
  • Close monitoring and appropriate management, including transfusions and potentially exchange procedures, are crucial for mitigating complications.

Related Experiment Videos